Autopsy report · NCT05101928

Ozurdex Monotherapy Trial

“The study was withdrawn due to insufficient participant enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Ottawa Hospital Research Institute

Sponsor type

University, hospital or other

Conditions

Uveitis, Posterior; Uveitis, Intermediate; Panuveitis

Interventions

Ozurdex 0.7mg Ophthalmic Implant; Prednisone

Participants

0

Sites

1

Countries

Canada

Trials that died the same way

• Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
  “Study was withdrawn due to lack of patient enrollment.” (92% match in meaning)
• BLOOM: Boldly Living outdOOrs for Mental Health
  “Study was withdrawn because available funding ended and could not be extended. No participants were enrolled.” (88% match in meaning)
• Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
  “The study was withdrawn due to not being able to recruit subjects.” (86% match in meaning)
• Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis
  “This study did not receive funding and was therefore withdrawn prior to enrollment of participants.” (85% match in meaning)
• Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
  “Withdrawn: study halted prematurely, prior to enrollment of first participant” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.